MNPR MONOPAR THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, MONOPAR THERAPEUTICS INC reported revenue of n/a, net income of −$5.31M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was $0.
MNPR annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$16.7M, net income −$13.7M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$16.2M, net income −$15.6M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$8.83M, net income −$8.40M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$10.5M, net income −$10.5M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$9.13M, net income −$9.10M (margin n/a), EPS −$0.73
MNPR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$5.31M, EPS n/a
- Quarter ended Mar 31, 2026: revenue $0, net income −$3.89M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$5.20M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.44M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.45M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.62M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$10.9M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.30M, EPS n/a
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.72M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.64M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.81M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.95M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.20M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.43M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$2.90M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.40M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.76M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.46M, EPS −$0.19
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.68M, EPS −$0.20
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.46M, EPS −$0.20
MNPR cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$12.2M, share buybacks $35.0M
- Fiscal year ended Dec 2024: operating cash flow −$6.40M, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow −$7.86M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.23M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$7.32M, share buybacks n/a
MNPR balance sheet
- Jun 30, 2026: cash $52.8M, total assets $135M, total liabilities $4.12M, shareholders' equity $131M
- Mar 31, 2026: cash $52.5M, total assets $138M, total liabilities $2.59M, shareholders' equity $135M
- Dec 31, 2025: cash $61.8M, total assets $141M, total liabilities $2.89M, shareholders' equity $138M
- Sep 30, 2025: cash $128M, total assets $144M, total liabilities $2.64M, shareholders' equity $142M
- Jun 30, 2025: cash $39.5M, total assets $53.9M, total liabilities $1.66M, shareholders' equity $52.2M
- Mar 31, 2025: cash $39.7M, total assets $55.1M, total liabilities $1.49M, shareholders' equity $53.6M
- Dec 31, 2024: cash $45.8M, total assets $60.3M, total liabilities $5.25M, shareholders' equity $55.0M
- Sep 30, 2024: cash $6.02M, total assets $6.07M, total liabilities $1.12M, shareholders' equity $4.95M
What is MNPR's revenue?
MONOPAR THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.
Is MNPR profitable?
No. MONOPAR THERAPEUTICS INC lost $17.8M over the last four quarters.